Merestinib is primarily investigated for its potential in cancer treatment due to its ability to inhibit multiple receptor tyrosine kinases involved in tumor growth and progression. It targets kinases such as MET, AXL, ROS1, and MERTK, which are often dysregulated in various cancers, including non-small cell lung cancer, hepatocellular carcinoma, and others. By blocking these signaling pathways, merestinib can suppress tumor cell proliferation, survival, and metastasis. It has been evaluated in clinical trials to assess its efficacy both as a monotherapy and in combination with other anticancer agents. Its broad kinase inhibition profile makes it a candidate for treating tumors with specific genetic alterations, especially those driven by MET amplification or ROS1 rearrangements. Additionally, merestinib’s activity against the TAM family of kinases (TYRO3, AXL, MERTK) suggests a role in modulating the tumor microenvironment and overcoming resistance to other targeted therapies. Research continues to explore optimal dosing, patient selection based on biomarkers, and potential combinations with immunotherapies or chemotherapy to enhance antitumor effects.